Coxiella burnetii is a Gram-negative, facultative intracellular microorganism that can 21 cause acute or chronic Q fever in human. It was recognized as an obligate intracellular 22 organism until the revolutionary design of an axenic cystine culture medium (ACCM).
Introduction 41
Coxiella burnetii is a Gram-negative, facultative intracellular pathogen and the 42 causative agent of human Q fever. The primary transmission route for human is 43 through inhalation of contaminated aerosols from the secretions and excretions of 44 domestic ruminants (1). C. burnetii infections in humans may manifest as an acute 45 disease (mainly as a self-limiting febrile illness, pneumonia, or hepatitis) or as a 46 chronic disease (mainly endocarditis in patients with previous valvulopathy) (2). The 47 majority (∼50-60%) of human infections are asymptomatic (2, 3). Chronic infections 48 are rare but can be fatal if untreated. C. burnetii is a significant cause of 49 culture-negative endocarditis in the United States (4). Treatment of chronic infections 50 is challenging and currently requires a combined antibiotic therapy with doxycycline 51 and hydroxychloroquine for at least 18 months (5). Worldwide only one vaccine for Q 52 fever called Q-Vax is licensed in Australia to protect high risk populations (6).
53
C. burnetii has two phase variants. Virulent C. burnetii isolated from natural 54 sources and infections is defined as phase I. It produces full-length LPS that may play 55 an important role in C. burnetii persistent infections by masking toll-like receptor 56 ligands from innate immune recognition by human dendritic cells (7) . LPS from phase 57 I C. burnetii contains two unique biomarkers of methylated sugars (virenose and 58 dihydrohydroxystreptose) at its O-specific chain. When extensively passaged in 59 immunoincompetent hosts, virulent phase I C. burnetii mutates to avirulent phase II (8, 60 9). LPS from phase II C. burnetii is severely truncated and only contains lipid A and 61 partial core oligosaccharide. Lipid A, the basal component of LPS, is essential for C. 62 burnetii growth in macrophage-like THP-1 cells but nonessential in non-phagocytic 63 cells (10).
64
The recent description of an axenic culture medium and the subsequent modified 65 axenic culture media provide invaluable tools for C. burnetii research (11) (12) (13) (14) (15) . The 66 first generation of axenic culture of C. burnetii requires a complex nutrient-rich 67 medium (Acidified Citrate Cysteine Medium, ACCM) and microaerophilic conditions 68 with 2.5% oxygen and 5% carbon dioxide (11). A second-generation medium 69 (ACCM-2) was generated by replacing fetal bovine serum with 70 methyl-beta-cyclodextrin (12), then was improved by supplementing tryptophan (14, 71 15). A nutritionally defined medium (ACCM-D) further improved C. burnetii growth 72 especially with increased bacterial viability (13). The continuous improvement of 73 axenic culture systems significantly facilitates the development of the C. burnetii 74 field.
75
Phase I C. burnetii is a category B select agent with potential for illegitimate use 76 and requires a biosafety level-3 laboratory for culture (16) . Phase II C. burnetii is 77 approved for use at biosafety level-2 and is widely used for studying the biology and 78 pathogenesis in tissue culture. The caveat of working with phase II C. burnetii is the 79 lack of animal models for assessing in vivo pathogenesis. To promote the 80 identification of virulence factors in phase II C. burnetii, an SCID mouse model was 81 recently established (17) . An alternative infection model using larvae of the greater 82 wax moth Galleria mellonella was also used to identify virulence factors in phase II C. 83 burnetii (18, 19) .
84
In this study, we characterized the growth of various C. burnetii strains under 85 different oxygen concentrations in ACCM-2 with or without tryptophan 86 supplementation. We found that, under normoxia if starting from an appropriated 87 concentration of freshly age inocula, C. burnetii Nine Mile phase II had significant 88 propagation in ACCM-2 supplemented with tryptophan. Under same conditions, a 89 Nine phase II transformant that contains a RSF1010-based shuttle vector can have 90 robust growth in ACCM-2 with or without tryptophan. Phase I C. burnetii had no 91 apparent growth under normoxia in ACCM-2 with or without tryptophan. Long-term 92 frozen stocks of all tested strains unanimously failed to have normoxic growth. In the 93 SCID mouse infection model, compared to wild type Nine Mile phase II, frozen 94 stocks of its transformant caused larger splenomegaly. Our data suggest that C. 95 burnetii retains functional genes for aerobic growth, and the expression of these genes 96 might be regulated by a temperature sensitive signal of the quorum sensing system.
97
Our data also suggest that the expression of genes relating to aerobic growth is 98 associated with enhanced in vivo virulence in C. burnetii. (Corning). The plates were placed in a tri-gas CO 2 incubator (2.5% oxygen and 5% 113 CO 2 ) or a CO 2 incubator (5% CO 2 ) for seven days at 37ºC. Each culture condition has 114 six replicates. ACCMs without tryptophan supplementation has been extensively investigated and 166 was reported to be microaerophilic (2.5% oxygen) (11, 12) . We repeated the 167 cultivation of wild type phase I and phase II C. burnetii in ACCM-2 without 168 tryptophan at different oxygen concentrations ( Figure 2AC ). In ACCM-2 without 169 tryptophan supplementation, these two strains grew normally at 2.5% oxygen but had 170 no significant growth at 20% oxygen, which is consistent with previous reports. In 171 ACCM-2 with tryptophan at 2.5% oxygen, both strains had similar growth yields ( Figure 2BD ). Interestingly, in ACCM-2 with tryptophan at 20% oxygen, wild type 173 phase II C. burnetii grew significantly (~2.5 logs increase) if starting from a high 174 concentration of fresh age inocula (~4×10^6 GE/mL), while phase I C. burnetii 175 consistently had no obvious growth. These results show tryptophan has subtly 176 different effects on the axenic growth of wild type phase I and phase II strains. Figure 4B, C) . The sizes of splenomegaly are in accordance with genome equivalents 208 in all infected mice ( Figure 4D ). Taken together, frozen stocks of phase II C. burnetii 209 transformants showed enhanced virulence in the SCID mouse model.
99

Materials and Methods
210
Discussion
211
The development of the axenic culture medium significantly advanced C. burnetii 212 research (11). The axenic culture medium for C. burnetii was continuously improved 213 (11) (12) (13) (14) . These medium studies found that hypoxic conditions are strictly required for 214 C. burnetii axenic replication. In this study, we characterized the axenic growth of 215 different C. burnetii strains in ACCM-2 with or without tryptophan supplementation, 216 especially their growth under normoxic conditions. Our goal was to further improve 217 the axenic culture of C. burnetii under normoxia. 218 We found that, under normoxic conditions if starting from appropriate 
228
The cytochrome bd oxidase, with its increased affinity for oxygen, is likely used by C. 229 burnetii under hypoxic conditions. The alternative terminal ubiquinol oxidase in C. phase II strains will be worthy of further investigation.
247
The normoxic cultures in this study were performed under static conditions. Given 
256
In conclusion, we characterized the growth of various C. burnetii strains in 257 ACCM-2 with or without tryptophan under normoxic and hypoxic conditions.
258
Consistent with previous reports, C. burnetii had robust growth under hypoxia. What 259 is surprising is that we found a C. burnetii phase II transformant and the wild type C. 
